PHASE III AXIS TRIAL OF AXITINIB VERSUS SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: ASIAN SUBGROUP ANALYSIS

被引：0
|
作者：
Uemura, H. [1 ]
Ou, Y. -C. [2 ]
Lim, H. Y. [3 ]
Tomita, Y. [4 ]
Ueda, T. [5 ]
Menon, H. [6 ]
Chung, J. [7 ]
Guo, J. [8 ]
Tarazi, J. [9 ]
Kim, S. [9 ]
Naito, S. [10 ]
Akaza, H. [11 ]
机构：
[1] Kinki Univ, Sch Med, Dept Urol, Osaka 589, Japan
[2] Taichung Vet Gen Hosp, Dept Surg, Taichung, Taiwan
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea
[4] Yamagata Univ, Fac Med, Dept Urol, Yamagata 990, Japan
[5] Chiba Canc Ctr, Dept Urol, Chiba 2608717, Japan
[6] Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India
[7] Natl Canc Ctr, Urol Oncol Clin, Gyeonggi Do, South Korea
[8] Peking Univ, Canc Hosp, Dept Renal Canc & Melanoma, Beijing 100871, Peoples R China
[9] Pfizer Oncol, La Jolla, CA USA
[10] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka 812, Japan
[11] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [31] Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma
    Zhang, Shannon
    CHINESE CLINICAL ONCOLOGY, 2015, 4 (01) : 15
  • [32] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
    Cheng, A.
    Kang, Y.
    Chen, Z.
    Tsao, C.
    Qin, S.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Guan, Z. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1
    Tsukamoto, Taiji
    Shinohara, Nobuo
    Tsuchiya, Norihiko
    Hamamoto, Yasuo
    Maruoka, Masayuki
    Fujimoto, Hiroyuki
    Niwakawa, Masashi
    Uemura, Hirotsugu
    Usami, Michiyuki
    Terai, Akito
    Kanayama, Hiro-omi
    Sumiyoshi, Yoshiteru
    Eto, Masatoshi
    Akaza, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (01) : 17 - 24
  • [34] Axitinib versus sorafenib as second-line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.
    Qin, Shukui
    Bi, Feng
    Cheng, Ying
    Guo, Jun
    Ren, Xiu Bao
    Huang, Yiran
    Wang, Jinwan
    Ben, Yong
    Kim, Sinil
    Tang, Jie
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
    Hutson, Thomas E.
    Escudier, Bernard
    Esteban, Emilio
    Bjarnason, Georg A.
    Lim, Ho Yeong
    Pittman, Kenneth B.
    Senico, Peggy
    Niethammer, Andreas
    Lu, Dongrui Ray
    Hariharan, Subramanian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 760 - +
  • [36] Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (vol 378, pg 1931, 2011)
    Rini, B., I
    Escudier, B.
    Tomczak, P.
    LANCET, 2012, 380 (9856): : 1818 - 1818
  • [37] Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
    Jun Guo
    Jie Jin
    Mototsugu Oya
    Hirotsugu Uemura
    Shunji Takahashi
    Katsunori Tatsugami
    Sun Young Rha
    Jae-Lyun Lee
    Jinsoo Chung
    Ho Yeong Lim
    Hsi Chin Wu
    Yen Hwa Chang
    Arun Azad
    Ian D. Davis
    Marlene J. Carrasco-Alfonso
    Bhupinder Nanua
    Jackie Han
    Qasim Ahmad
    Robert Motzer
    Journal of Hematology & Oncology, 11
  • [38] Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
    Guo, Jun
    Jin, Jie
    Oya, Mototsugu
    Uemura, Hirotsugu
    Takahashi, Shunji
    Tatsugami, Katsunori
    Rha, Sun Young
    Lee, Jae-Lyun
    Chung, Jinsoo
    Lim, Ho Yeong
    Wu, Hsi Chin
    Chang, Yen Hwa
    Azad, Arun
    Davis, Ian D.
    Carrasco-Alfonso, Marlene J.
    Nanua, Bhupinder
    Han, Jackie
    Ahmad, Qasim
    Motzer, Robert
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [39] Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis
    Wang, Hai
    Man, Libo
    Li, Guizhong
    Huang, Guanglin
    Wang, Jianwei
    ONCOTARGETS AND THERAPY, 2016, 9 : 3423 - 3432
  • [40] PROGRESSION FREE SURVIVAL VS OVERALL SURVIVAL: AN EXAMPLE FROM RANDOMISED PHASE III TRIAL WITH AXITINIB (AXIS) IN METASTATIC RENAL CELL CARCINOMA
    Alam, Mahmood
    Delahoy, Philippa
    Park, Simon H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 306 - 306
12345